Literature DB >> 30170925

Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.

Rui Yang1, Yu Chen1, Liangkun Pan1, Yanyan Yang1, Qiang Zheng1, Yue Hu2, Yuxi Wang1, Liangren Zhang1, Yang Sun2, Zhongjun Li1, Xiangbao Meng3.   

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1) is regarded as a promising target for cancer immunotherapy. Many naphthoquinone derivatives have been reported as IDO1 inhibitors so far. Herein, two series of naphthoquinone derivatives, naphthoindolizine and indolizinoquinoline-5,12-dione derivatives, were synthesized and evaluated for their IDO1 inhibitory activity. Most of the target compounds showed significant inhibition potency and high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO). The structure-activity relationship was also summarized. The most potent compounds 5c (IC50 23 nM, IDO1 enzyme), and 5b' (IC50 372 nM, HeLa cell) were identified as promising lead compounds.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Indoleamine 2,3-dioxygenase 1; Indolizinoquinoline-5,12-dione derivatives; Naphthoindolizine

Mesh:

Substances:

Year:  2018        PMID: 30170925     DOI: 10.1016/j.bmc.2018.08.028

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.

Authors:  Huizhen Ge; Longfei Mao; Jie Zhao; Yuwei Wang; Danfeng Shi; Xing Yang; Xiaorui Wang; Huanxiang Liu; Xiaojun Yao
Journal:  J Comput Aided Mol Des       Date:  2021-04-27       Impact factor: 3.686

Review 2.  IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.

Authors:  Yi-Shu Huang; Joy Ogbechi; Felix I Clanchy; Richard O Williams; Trevor W Stone
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.